| Company Name: |
Taizhou Zhongzhi Biotechnology Co., Ltd Gold
|
| Tel: |
13012344321 |
| Email: |
3995296515@qq.com |
| Products Intro: |
Product Name:Reproxalap (ADX-102)
CAS:916056-79-6
Purity:98%+ Package:10g;100g;1kg;10kg
|
ADX-102 (NS-2) manufacturers
- Reproxalap
-
- $33.00 / 5mg
-
2025-07-12
- CAS:916056-79-6
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | ADX-102 (NS-2) Basic information |
| Product Name: | ADX-102 (NS-2) | | Synonyms: | ADX-102 (NS-2);Reproxalap;2-Quinolinemethanol, 3-amino-6-chloro-α,α-dimethyl-;ADX-102 (Reproxalap;2-(3-Amino-6-chloroquinolin-2-yl)propan-2-ol;Reproxzlap;Reproxalap (ADX-102);Inhibitor,NS 2,Reproxalap,ADX 102,ADX102,inhibit,NS2 | | CAS: | 916056-79-6 | | MF: | C12H13ClN2O | | MW: | 236.7 | | EINECS: | | | Product Categories: | | | Mol File: | 916056-79-6.mol |  |
| | ADX-102 (NS-2) Chemical Properties |
| Boiling point | 410.5±40.0 °C(Predicted) | | density | 1.324±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (422.48 mM; Need ultrasonic) | | form | Solid | | pka | 13.07±0.29(Predicted) | | color | Light yellow to yellow | | InChI | InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3 | | InChIKey | GUHFUVLKYSQIOQ-UHFFFAOYSA-N | | SMILES | CC(C1=C(N)C=C2C(=N1)C=CC(Cl)=C2)(O)C |
| | ADX-102 (NS-2) Usage And Synthesis |
| Uses | Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis[1][2][3][4][5]. | | in vivo | Reproxalap (30-100 mg/kg, once or twice a day) shows a dose-dependent reduction in pain-related behaviors in acute pain models[3].
Reproxalap (10 mg/kg, intraperitoneal injection, single dose) significantly reduces the formation of N-retinyl-phosphatidylethanolamine (A2E) in the retinas of mice with macular degeneration[5].
Reproxalap (25-50 μg, IVT, injected in five doses after LPS (HY-D1056) induction) can improve eye scores in uveitis rats[5]. | Animal Model: | Carrageenaninduced and Complete Freund’s Adjuvant (CFA)-induced models in mice[3] | | Dosage: | 30, 100 mg/kg; once a day or twice a day | | Administration: | | | Result: | Was effective in thermal hyperalgesia in the CFA-induced model at both 100 mg/kg QD and BID doses; in the carrageenan-induced model, and was effective at 30 mg/kg BID and 100 mg/kg BID doses.
Was effective in mechanical allodynia only in the CFA-induced model at a 100 mg/kg BID dose; in the carrageenan-induced model, was not effective.
Had a mild effect on swelling in the CFA-induced model at 30 mg/kg BID and 100 mg/kg BID doses; in the carrageenan-induced model, had a mild effect at a 100 mg/kg QD dose. |
| Animal Model: | A mouse knockout model (abcr-/-) of macular degeneration (MD) [5] | | Dosage: | 10 mg/kg; single dose
| | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced the formation of N-retinylidene-N-retinylethanolamine (A2E) in the retina by 71% without affecting dark adaptation or body weight. |
| Animal Model: | A rat model of lipopolysaccharide (LPS)-induced uveitis[5] | | Dosage: | 10 mg/kg
50 μg at hours 1, 3, 7, 10 and 17, after LPS induction, or injection 25 μg at 1 hour after LPS induction | | Administration: | Intravitreal (IVT) | | Result: | Improved the eye examination scores, enhancing the retinal-choroidal ratings. |
| | IC 50 | PKCα; Caspase 3; Caspase-7 | | References | [1] Ochoa CA, et al. Aldehyde Trapping by ADX-102 Is Protective against Cigarette Smoke and Alcohol Mediated Lung Cell Injury. Biomolecules. 2022 Mar 2;12(3):393. DOI:10.3390/biom12030393
[2] Rizzo WB, et al. Sj?gren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents. Mol Genet Metab Rep. 2021 Dec 23;30:100839. DOI:10.1016/j.ymgmr.2021.100839
[3] Susan Macdonald, et al. ADX-102, a novel aldehyde trap, reduces nociceptive behavior in mouse models of carrageenan and CFA induced pain.
[4] Reproxalap Phase 2b Dry Eye Disease Results.
[5] Susan G. Macdonald, Ph.D., et al. Novel Small Molecule Aldehyde Sequestering Agents Demonstrate Broad Therapeutic Potential for Ocular Inflammation. |
| | ADX-102 (NS-2) Preparation Products And Raw materials |
|